Eribulin for Advanced Breast Cancer: A Drug Evaluation / 한국유방암학회지
Journal of Breast Cancer
;
: 12-15, 2013.
Artigo
em Inglês
| WPRIM
| ID: wpr-36141
ABSTRACT
Eribulin is a synthetic microtubule dynamics inhibitor that was developed from a marine natural product halichondrin B. It exhibited in vitro and in vivo activities against a wide number of malignancies. A number of advanced phase trials showed improved survival following eribulin treatment in pretreated advanced breast cancer patients. This review provides an overview of the background to the therapeutic use of eribulin in oncology, including its pharmacology, pharmacokinetics, clinical efficacy, safety, and potential economic factors.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Mama
/
Neoplasias da Mama
/
Macrolídeos
/
Avaliação de Medicamentos
/
Éteres Cíclicos
/
Furanos
/
Cetonas
/
Microtúbulos
Limite:
Humanos
Idioma:
Inglês
Revista:
Journal of Breast Cancer
Ano de publicação:
2013
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS